This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2023 Feb 18;3(1):ltad002.

doi: 10.1093/immadv/ltad002. eCollection 2023.

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

No authors listed

PMID: 36819977
PMCID: PMC9938635
DOI: 10.1093/immadv/ltad002

Published Erratum

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

No authors listed. Immunother Adv. 2023.

. 2023 Feb 18;3(1):ltad002.

doi: 10.1093/immadv/ltad002. eCollection 2023.

PMID: 36819977
PMCID: PMC9938635
DOI: 10.1093/immadv/ltad002

Abstract

[This corrects the article DOI: 10.1093/immadv/ltac019.].

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.

PubMed Disclaimer

Erratum for

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS, Verneret M, Fan H, Hu T, Xu F, Taraszka J, Pelletier M, Miyashiro J, Rinne M, Dranoff G, Sabatos-Peyton C, Cremasco V. Schwartz S, et al. Immunother Adv. 2022 Aug 10;2(1):ltac019. doi: 10.1093/immadv/ltac019. eCollection 2022. Immunother Adv. 2022. PMID: 36196369 Free PMC article.

Similar articles

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS, Verneret M, Fan H, Hu T, Xu F, Taraszka J, Pelletier M, Miyashiro J, Rinne M, Dranoff G, Sabatos-Peyton C, Cremasco V. Schwartz S, et al. Immunother Adv. 2022 Aug 10;2(1):ltac019. doi: 10.1093/immadv/ltac019. eCollection 2022. Immunother Adv. 2022. PMID: 36196369 Free PMC article.
Correction.
[No authors listed] [No authors listed] Immunother Adv. 2022 Aug 11;2(1):ltac018. doi: 10.1093/immadv/ltac018. eCollection 2022. Immunother Adv. 2022. PMID: 35967910 Free PMC article.
Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
[No authors listed] [No authors listed] Immunother Adv. 2023 Oct 12;3(1):ltad018. doi: 10.1093/immadv/ltad018. eCollection 2023. Immunother Adv. 2023. PMID: 37841366 Free PMC article.
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.
Gomes de Morais AL, Cerdá S, de Miguel M. Gomes de Morais AL, et al. Curr Oncol Rep. 2022 May;24(5):651-658. doi: 10.1007/s11912-022-01218-y. Epub 2022 Feb 26. Curr Oncol Rep. 2022. PMID: 35218498 Review.
TIM-3 pathway dysregulation and targeting in cancer.
Zeidan AM, Komrokji RS, Brunner AM. Zeidan AM, et al. Expert Rev Anticancer Ther. 2021 May;21(5):523-534. doi: 10.1080/14737140.2021.1865814. Epub 2021 Jan 19. Expert Rev Anticancer Ther. 2021. PMID: 33334180 Review.

See all similar articles

Cited by

Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.
Wang Z, Feng S, Yao X, Zhao R, Li Y, Zheng M, Li Z, Wang Y. Wang Z, et al. Front Immunol. 2025 Jul 9;16:1620895. doi: 10.3389/fimmu.2025.1620895. eCollection 2025. Front Immunol. 2025. PMID: 40703518 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program